Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
Gastric cancer patients who are malnourished prior to treatment faced worse treatment outcomes compared to those who maintained proper nutrition, according to... Read More
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
The PD-L1 inhibitor Bavencio, when given as maintenance therapy to gastric cancer patients in a trial, was not superior to chemotherapy, but... Read More
Blood test picks out cancers likely to benefit from targeted drugs
British researchers discovered that a blood test could identify gastric cancer patients who might benefit from EGFR-inhibiting drugs.
Gastric Cancer Registry Prepares to Launch Innovative Data Portal
The Gastric Cancer Registry is the first comprehensive repository of clinical and genomic data pertaining to stomach cancer. Its chief aims are... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer slowed down... Read More
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
